Results 41 to 50 of about 12,992 (201)

The Comprehensive Live Cell‐Based Cytotoxicity Assay for Monitoring Disease Activity and Guiding Rescue Therapy in Acute Attacks of NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neuromyelitis optica spectrum disorder (NMOSD) is a devastating neurological disease that lacks serological biomarkers that can accurately reflect disease activity. We established a live cell‐based assay (LCBA) using serum with endogenous complement to quantify the overall cytotoxicity, offering a novel functional tool for monitoring
Xiaona Xu, Jie Ding, Yupeng Du, Guibao Luo, Jinming Li, Rui Liu, Xiaoyi Xu, Xiao Li, Minshu Li, Wei Jiang, Chunsheng Yang   +10 more
wiley   +1 more source

Eculizumab-related progressive multifocal leukoencephalopathy

, 2015
Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection of the CNS caused by reactivation of the polyomavirus JC (JCV). In the context of immunosuppression, JCV can reactivate and spread to brain infecting oligodendrocytes ...
Ivanovic Barbeito, Yerko, Ramos González, Ana, Gómez Cibera, Emilio, Villarejo Galende, Alberto, Hilario Barrio, Amaya, Gutiérrez Martínez, Eduardo, Abradelo De Usera, Manuel, Ruíz Morales, Juan, Morales Ruiz, Enrique   +8 more
core   +1 more source

Data_Sheet_2_Utilization Pattern for Eculizumab Among Children With Hemolytic Uremic Syndrome.PDF

, 2021
Background: Hemolytic uremic syndrome (HUS) is a complex disease with multi-organ involvement. Eculizumab therapy is recommended for treatment of complement mediated hemolytic uremic syndrome (cHUS).
Rachel Millner (11522578), Parthak Prodhan (11522584), Richard Blaszak (11522575), Saritha Ranabothu (11522572), Clare C. Brown (9509210), Kristen Rice Moore (11522581)   +5 more
core   +1 more source

Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis

Annals of Clinical and Translational Neurology
Objective Eculizumab and ravulizumab are complement protein C5 inhibitors, showing efficacy and tolerability for patients with anti‐acetylcholine receptor‐positive (AChR+) generalized myasthenia gravis (gMG) in phase 3 clinical trials and subsequent ...
Daiki Tokuyasu, Shigeaki Suzuki, Akiyuki Uzawa, Yuriko Nagane, Masayuki Masuda, Shingo Konno, Tomoya Kubota, Makoto Samukawa, Takamichi Sugimoto, Kei Ishizuchi, Munenori Oyama, Manato Yasuda, Hiroyuki Akamine, Yosuke Onishi, Yasushi Suzuki, Naoki Kawaguchi, Naoya Minami, Takashi Kimura, Masanori P. Takahashi, Hiroyuki Murai, Kimiaki Utsugisawa   +20 more
doaj   +1 more source

Structural Basis of Shiga Toxin Neutralization by Human Antibodies Targeting Canonical Receptor‐Binding and Non‐Canonical Assembly Sites

Advanced Science, EarlyView.
Cryo‐electron microscopy structures reveal two distinct neutralization mechanisms of fully human monoclonal antibodies targeting the Shiga toxin 1a B subunit. RDS059 occludes the Gb3 receptor‐binding site, whereas RDS045 engages a lateral quaternary epitope to disrupt holotoxin assembly.
Jianting Ke, Xin Li, Xiaoli Wang, Zhaoxia Huang, Shaojie Xue, Yuyang Liu, Jing Pan, Guowei Hu, Yayu Wang, Cheng Wang, Shoudeng Chen   +10 more
wiley   +1 more source

How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome [PDF]

, 2014
Thrombotic thrombocytopenic purpura (TTP) and atypical haemolytic uraemic syndrome (aHUS) are acute, rare life-threatening thrombotic microangiopathies that require rapid diagnosis and treatment.
Goodship, T, Scully, M
core  

Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab

, 2017
Pregnancy-associated atypical haemolytic uraemic syndrome (P-aHUS) is a rare, potentially lethal condition that can complicate pregnancy in up to 1 in 25 000 cases. Without prompt diagnosis and initiation of appropriate treatment, this condition can lead
Kurtkoti, Jagadeesh, Aye San, Gately, Ryan, Alan Parnham, Parnham, Alan, Ryan Gately, San, Aye, Jagadeesh Kurtkoti   +7 more
core   +1 more source

Pharmacokinetics and Pharmacodynamics Estimation of Eculizumab in a 2-Year-Old Girl With Atypical Hemolytic Uremic Syndrome: A Case Report With 4-Year Follow-Up

Frontiers in Pediatrics, 2019
Background: Eculizumab has dramatically changed poor outcomes of complement-mediated atypical hemolytic uremic syndrome (aHUS) as first-line treatment. Discontinuation of eculizumab remains challenging, and doctor's visits every 2 weeks for intravenous ...
Ken Saida, Tsuyoshi Fukuda, Kana Mizuno, Masao Ogura, Koichi Kamei, Shuichi Ito   +5 more
doaj   +1 more source

Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study

EClinicalMedicine, 2020
Background: Complement pathway inhibition may provide benefit for severe acute respiratory illnesses caused by viral infections such as COVID-19. We present results from a nonrandomized proof-of-concept study of complement C5 inhibitor eculizumab for ...
Djillali Annane, Nicholas Heming, Lamiae Grimaldi-Bensouda, Véronique Frémeaux-Bacchi, Marie Vigan, Anne-Laure Roux, Armance Marchal, Hugues Michelon, Martin Rottman, Pierre Moine   +9 more
doaj   +1 more source

Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal Hemoglobinuria with a Suboptimal Response to Prior Eculizumab Treatment

Hematology Reports, 2023
European Society for Blood and Marrow Transplantation (EBMT) hematologic response categories comprehensively assess complement inhibitor responses in patients with paroxysmal nocturnal hemoglobinuria (PNH).
Jesse Fishman, Seri Anderson, Sandra E. Talbird, David Dingli   +3 more
doaj   +1 more source